Irwin Naturals Inc. CEO Klee Irwin tells Proactive it achieved record results for the financial year ended December 31, 2021, with the growth of its core business fueling the roll-up of the company’s psychedelic mental health clinics.
Operating revenue reached a record $100.34 million last year, a rise of 12.3% on 2020, while fourth-quarter revenue climbed 5.9% to $25.94 million, the company noted.
Irwin Naturals said it intends to leverage its household name brand status to drive an “aggressive" roll-up of mental health clinics. The company is focused on ketamine clinics, as this is currently the only psychedelic substance approved by the FDA.